ReviewBiomedical journal2025
"Mpox in MSM: Tackling stigma, minimizing risk factors, exploring pathogenesis, and treatment approaches".
Review in Biomedical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Sentinel serosurvey for Mpox virus infection among key populations in India: Evidence of sporadic past exposure beyond travel-related cases.The Indian journal of medical research · 2026Article
- Rethinking mpox: epidemiology, clinical variants, diagnosis, and response.Osong public health and research perspectives · 2026Article
- Retrospective Study of Epidemiological and Clinical Characteristics of Mpox-HIV Coinfection in Men Who Have Sex with Men in Hangzhou, China.AIDS and behavior · 2026Article
- Long-term trends in HIV-related stigma among older adults with and without HIV: a cohort study from Mbarara, Uganda.The Gerontologist · 2026Article
- In Silico Design and Computational Characterization of Novel Chimeric Multiepitope Antigens for Mpox Serosurveillance: An Immunoinformatics Approach.Health science reports · 2026Article
- Trends of Pathogenicity and Potential Risk Evaluation of Central African Mpox Variant to Cause Global Public Health Emergency: A Cross-Sectional Analysis.Health science reports · 2026Article
- Mpox Outbreak in the East Africa Region: Current Status, Containment Measures, Challenges, and Future Direction.Public health challenges · 2026Review
- Decoding cross-talk between Mpox and HIV: insights from transcriptomics and network-based analyses.Virology journal · 2025Article
- Article
- Mpox-Related Stigma Among Gay, Bisexual, and Other Men Who Have Sex with Men: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Assessment of healthcare workers' knowledge and attitudes toward mpox and acceptance of its vaccine: a health belief model-based analysis in the Gulf region.Osong public health and research perspectives · 2025Article
- A Comparative Analysis of Global Responses to Monkeypox Outbreaks: Lessons Learned and Future Directions - a Mini Narrative Review.Annals of medicine and surgery (2012) · 2025Review
- Breaking Diagnostic Barriers: Vision Transformers Redefine Monkeypox Detection.Diagnostics (Basel, Switzerland) · 2025Article
- Monkeypox virus and type 1 diabetes: a molecular insight into inflammatory signaling and β-cell autoimmunity.Virology journal · 2025Review
- Mpox Infection and Endocrine Health: Bridging the Knowledge Gap.Medicina (Kaunas, Lithuania) · 2025Review
- Evaluating the Antiviral Potential of Polyherbal Formulation (Life (Basel, Switzerland) · 2025Article
- Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.Advanced healthcare materials · 2025Review
- Recurrent Mpox: divergent virulent clades and the urgent need for strategic measures including novel vaccine development to sustain global health security.BMC infectious diseases · 2025Review
- Inherently imperfect, inherently evolving - The pursuit of precision through biomarkers.Biomedical journal · 2025Article
- Mpox Cases in Serbia, 2022.Infectious disease reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox is a zoonotic disease caused by the monkeypox virus (MPV), primarily found in Central and West African countries. The typical presentation of the disease before the 2022 mpox outbreak includes a febrile prodrome 5-13 days post-exposure, accompanied by lymphadenopathy, malaise, headache, and muscle aches. Unexpectedly, during the 2022 outbreak, several cases of atypical presentations of the disease were reported, such as the absence of prodromal symptoms and the presence of genital skin lesions suggestive of sexual transmission. As per the World Health Organization (WHO), as of March 20, 2024, 94,707 cases of mpox were reported worldwide, resulting in 181 deaths (22 in African endemic regions and 159 in non-endemic countries). The United States Centers for Disease Control and Prevention (CDC) reports a total of 32,063 cases (33.85% of total cases globally), with 58 deaths (32.04% of global deaths) due to mpox. Person-to-person transmission of mpox can occur through respiratory droplets and sustained close contact. However, during the 2022 outbreak of mpox, a high incidence of anal and perianal lesions among MSMs indicated sexual transmission of MPV as a major route of transmission. Since MSMs are disproportionately at risk for HIV transmission. In this review, we discusses the risk factors, transmission patterns, pathogenesis, vaccine, and treatment options for mpox among MSM and people living with HIV (PLWH). Furthermore, we provide a brief perspective on the evolution of the MPV in immunocompromised people like PLWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.